Press release
Radiopharmaceutical Theranostics Market Recent Trends, In-depth Analysis, Size and Forecast to 2028
The Radiopharmaceutical Theranostics Market is expected to reach US$ 3,441.97 million by 2028 from US$ 1,814.58 million in 2022; it is estimated to grow at a CAGR of 11.3% from 2022 to 2028.
The rising incidence of cancer and rising application in treatment of cardiovascular disorder are among the key forces bolstering the market. However, regulatory challenges for the approval of radiopharmaceutical theranostics hinder the radiopharmaceutical theranostics market growth.
Radiopharmaceuticals are important in the diagnosis and therapy of cancer; a diagnostic scan with 123I, 124I, or low-activity 131I-iodide is followed by therapy with high-activity 131I-iodide. Similarly, adrenergic tumors such as pheochromocytoma and neuroblastoma can be imaged with 123 I-meta-iodobenzylguanidine and treated with 131 I-metaiodobenzylguanidine. Bone scintigraphy can be used to select patients with painful bone metastases that progressed from prostate cancer. They might benefit from treatment with beta- or alpha-particle-emitting bone-seeking agents, the newest and most successful of which is 223Ra radium chloride. Somatostatin receptor targeting peptides for diagnosing and treating neuroendocrine tumors with agents such as 68Ga-DOTATATE and 177Lu-DOTATATE, respectively, are among the recently established theranostics.
Get Exclusive Sample PDF @: https://www.premiummarketinsights.com/sample/TIP00073774?utm_source=OpenPr&utm_medium=10640
The List of Companies -
1. Bayer AG
2. GE HealthCare Technologies Inc
3. Curium
4. Lantheus Medical Imaging, Inc.
5. Telix Pharmaceuticals Ltd.
6. Cardinal Health Inc
7. Advanced Accelerator Applications S.A.
8. Jubilant Radiopharma
9. Theragnostics
10. NuView Life Sciences
Cancer is one of the leading causes of death worldwide, responsible for almost 10 million deaths in 2020, or almost one in six. The most common types of cancer are breast, lung, colon, and prostate. According to National Cancer Registry Program Report 2020, in India, male cancer cases were estimated at 679,421 in 2020 and are expected to further increase to about 763,575 in 2025, while female cancer cases were estimated at 712,758 in 2020 and 806,218 in 2025. As people age, they become immunocompromised and often succumb to cancer risks. Poor lifestyles, longer working hours, increasingly stressful lives, smoking, alcohol consumption, contraceptive use, nulliparity, and reduced breastfeeding all contribute to breast cancer incidence.
According to the American Cancer Society's 2023 report, ~43,720 new cases of thyroid cancer (12,540 in men and 31,180 in women) are recorded in 2023. The report also revealed that 2,120 deaths occurred from thyroid cancer (970 in men and 1,150 in women) in the same year. Radiopharmaceutical theranostics have promising potential in cancer therapy. Theranostics is the combination of therapeutic and diagnostic techniques that utilize a suitable radiopharmaceutical agent. For example, radioiodine has a well-known theranostic application in diagnosing and treating differentiated thyroid cancer. Several radiopharmaceutical theranostic pairs are available for breast cancer applications. These pairs include 43/44Sc/47Sc, 64Cu/67Cu, 83Sr/89Sr, 86Y/90Y, 110In/111In, 124I/131I, 152Tb/161Tb, 152Tb/149Tb, 68Ga/177Lu, and 90Y/177Lu. 123I/131I is a well-known example of theranostic pair that is used in high-quality single-photon emission computerized tomography (SPECT)/CT for pre- and post-therapeutic assessment of thyroid cancer.
Get full Report Description, TOC, Table of Figure, Chart, etc. @: https://www.premiummarketinsights.com/reports-tip/radiopharmaceutical-theranostics-market
Malignant gliomas are deadly tumors with the availability of only a few therapeutic options. 89Zr- and 177Lu-labeled Lumi804-αCD11b is a promising theranostic technique intended for monitoring and reducing tumor-associated myeloid cells (TAMCs) in gliomas and improving immunotherapy outcomes. Further, theranostics are incorporated in radiometals for PET imaging and targeted radiopharmaceutical therapy (TRT). DOTA-octreotate (dotatate) radiolabeled with Lu-177 (177Lu-dotatate: Lutathera) or Ga-68 (68Ga-dotatate: NetSpot) are approved by the Food and Drug Administration (FDA) for targeted radiopharmaceutical therapy (TRT) and positron emission tomography (PET) imaging. Thus, a radiopharmaceutical theranostic approach has unprecedented value in diagnosing and treating different types of cancer, which fuels the overall radiopharmaceutical theranostics market growth.
Product Type Insights
Based on product type, the radiopharmaceutical theranostics market is segmented positron emission tomography (PET) tracers, beta emitters, and alpha emitters. In 2022, the positron emission tomography (PET) tracers segment held the largest market share in radiopharmaceutical theranostics market, and it is anticipated to register the highest CAGR during the forecast period (2022-2028). PET is an imaging technique that provides quantitative information on the distribution of PET radiopharmaceuticals in the body. PET imaging requires expensive equipment, which includes a cyclotron for radionuclide production, automated chemistry devices, purification instrumentation, and PET cameras.
PET imaging is used in areas such as cardiology, neurology, and cancer diagnosis. PET may detect the early onset of disease before it is evident on other imaging tests. Better resolution can be achieved via PET using positron emitters, such as gallium-68 and fluorine-18. PET tracers featuring radioactive copper have also been developed as a promising alternative for existing hypoxia imaging techniques due to their high membrane permeability and low redox potential. The success of Ga-PSMA-11 further inspired the development of PSMA-targeting PET tracers for imaging prostate cancer. Additionally, theranostics PET tracers are progressively used in radiopharmaceutical drug development and its application.
Theranostic PET tracers have the potential to serve as a noninvasive whole-body navigator, which helps select the most effective drug candidates, and determine optimal dosage and administration route. Thus, benefits such as higher resolution, and quantification of activity boost the radiopharmaceutical theranostics market for the PET tracers segment.
Radioisotope Insights
Based on radioisotope, the radiopharmaceutical theranostics market is segmented Lutetium (Lu) 177, Gallium-68, Iodine-131, Iodine-123, Technetium-99, Yttrium-90 (Y-90), Copper (Cu) 64, 18F, Copper (Cu) 67, and others. In 2022, the Lutetium (Lu) 177 segment held the largest market share in radiopharmaceutical theranostics market, and it is anticipated to register the highest CAGR of 12.3% during the forecast period (2022-2028). Lutetium-177 (177Lu) is the latest addition to the field of nuclear medicine. It has potential to become one of the most extensively used therapeutic radionuclides in the coming years. Lu-177 PSMA therapy for cancer theranostic is employed to treat advanced prostate cancer cases. Lu-177 octreotate therapy is used to treat neuroendocrine tumors (NETs), including head and neck cancers and gastrointestinal tumors. Lutetium therapy (lutetium-177-DOTA-oxodotreotide) has been identified as targeted radionuclide therapy or peptide receptor radionuclide therapy (PRRT). The US Food and Drug Administration (FDA) has approved 177Lu-labeled DOTA-TATE for peptide receptor radionuclide therapy (PRRT).
Buy this research report at @: https://www.premiummarketinsights.com/buy/TIP00073774?utm_source=OpenPr&utm_medium=10640
Source Insights
Based on source, the radiopharmaceutical theranostics market is divided into cyclotrons and nuclear reactors. In 2022, the cyclotrons segment held a larger market share in radiopharmaceutical theranostics market and is anticipated to register a higher CAGR during the forecast period (2022-2028). Cyclotrons are best suited for producing proton-rich radioisotopes such as Fluorine-18 (18F).
Commercially available cyclotron-produced medical radioisotope involves Carbon-11, Nitrogen-13, Oxygen-15, Fluorine-18 (18F), Copper-64, Gallium-67, Iodine-123, and Thallium-201. According to the International Atomic Energy Agency (IAEA) 2023 report, the most frequent radioisotope produced through cyclotrons are those with short half-lives, particularly fluorine-18, carbon-11, oxygen-15, and nitrogen-13, intended for imaging techniques such as positron emission tomography (PET). Cyclotrons account for almost 95% of the production of radiopharmaceuticals used in PET. Additionally, the demand for cyclotrons is increasing as radionuclides are majorly used in research, diagnosis, and treatment of a range of life-threatening diseases such as cancer, Parkinson's, Alzheimer's, and insomnia. Further, medical imaging techniques such as PET and SPECT depend on cyclotron-produced radioisotopes.
Application Insights
Based on application, the radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and companion diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in radiopharmaceutical theranostics market in 2022, and it is expected to register a higher CAGR during the forecast period. Targeted therapeutics have emerged as a promising strategy for treating harmful clinical conditions, such as cancer. For example, "radionuclide," a type of radiation therapy, uses a cell-targeting molecule such as a monoclonal antibody injected into the body. Further, the cell-targeting molecule binds to a specific target molecule on cancer cells, subsequently killing the targeted cancer cells; the mechanism ensures minimum harm to normal cells. Targeted therapeutics are used for treating prostate cancer and other types of cancers. This is well understood by the following case of targeting somatostatin receptors in neuroendocrine pancreatic tumors.
68Ga has been developed for somatostatin receptor imaging such as DOTATOC, DOTATATE, and DOTANOC. A somatostatin-receptor targeted therapy can be utilized for neoadjuvant therapy that renders inoperable pNET resectable by utilizing 177Lu-DOTATATE (27) and 90Y-DOTATATE (28). 90Y is a beta-emitting radionuclide best suited for bulky pancreatic tumors. Additionally, 177Lu-DOTATOC and 213Bi-DOTATOC have revealed relatively high biological effectiveness, and they are effectively responsible for decreasing the survival of pancreatic adenocarcinoma cells.
Indication Insights
Based on indication, the radiopharmaceutical theranostics market is segmented oncology, neurology, cardiology, and others. The oncology segment held the largest market share in radiopharmaceutical theranostics market in 2022, and it is anticipated to register the highest CAGR during the forecast period (2022-2028). Theranostics methods involve administering nanoparticles into the patient's body and using photodynamic therapy, which paves the way for personalized medicine. These methods can be applied in the treatment of esophageal cancer, prostate cancer, and breast cancer, in the treatment of actinic keratosis, actinic cheilitis, Bowen's disease, basal cell epithelioma, and macular degeneration.
Therapeutic radiopharmaceuticals for cancer treatment are predominantly labeled with beta-emitting radionuclides. The radionuclides I-131, Lu-177, and Yttrium-90 (Y-90) are frequently used for this purpose. Upon decay, the emitted beta-particles travel 1-12 mm through tissue while losing energy and causing cytotoxic damage to the cell to induce apoptosis. Alternatively, and more recently, alpha-emitting radionuclides, e.g., At-211 or Ac-225, have been explored for therapeutic applications. Theranostics has been successfully used by clinicians and patients in treating prostate cancer. Thus, the strong clinical need for these therapies and targeted treatments in oncology continue to fuel the market for the oncology segment during the forecast period.
End User Insights
Based on end user, the radiopharmaceutical theranostics market is segmented hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022 of global radiopharmaceutical theranostics market. However, academic and research institutes segment is anticipated to register the highest CAGR during the forecast period (2022-2028). Hospitals employ technologically advanced systems to treat cardiac aneurysms, neurology aneurysms, oncology tumors, and other similar conditions. The rising prevalence of various diseases and an increasing number of hospitals contribute to the growth of the radiopharmaceutical theragnostic market for hospitals segment.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 by Product Type
1.3.2 by Radioisotope
1.3.3 by Source
1.3.4 by Application
1.3.5 by Indication
1.3.6 by End User
1.3.7 by Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 South & Central America PEST Analysis
4.2.5 Middle East & Africa PEST Analysis
4.3 Expert's Opinion
5. Key Market Dynamics
Continued…
Other Reports:
Smart Pest Monitoring Management System Market Growth, Future Prospects And Competitive Analysis (2022-2028 https://www.marketwatch.com/press-release/smart-pest-monitoring-management-system-market-growth-future-prospects-and-competitive-analysis-20222028-2023-05-12?mod=search_headline
Traffic Management Market Size, Share, Global Trends, Major Key Players and Geographical Forecast Till 2028 https://www.marketwatch.com/press-release/traffic-management-market-size-share-global-trends-major-key-players-and-geographical-forecast-till-2028-2023-05-12?mod=search_headline
Wire And Cable Market by Historical Data, Segmentation, Growth Opportunities Forecast till 2028 https://www.marketwatch.com/press-release/wire-and-cable-market-by-historical-data-segmentation-growth-opportunities-forecast-till-2028-2023-05-12?mod=search_headline
Aircraft Isothermal Forging Market Size, Share & Global Insights 2022-2028 https://www.marketwatch.com/press-release/aircraft-isothermal-forging-market-size-share-global-insights-2022-2028-2023-05-12?mod=search_headline
Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email: sales@premiummarketinsights.com
About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.
The rising incidence of cancer and rising application in treatment of cardiovascular disorder are among the key forces bolstering the market. However, regulatory challenges for the approval of radiopharmaceutical theranostics hinder the radiopharmaceutical theranostics market growth.
Radiopharmaceuticals are important in the diagnosis and therapy of cancer; a diagnostic scan with 123I, 124I, or low-activity 131I-iodide is followed by therapy with high-activity 131I-iodide. Similarly, adrenergic tumors such as pheochromocytoma and neuroblastoma can be imaged with 123 I-meta-iodobenzylguanidine and treated with 131 I-metaiodobenzylguanidine. Bone scintigraphy can be used to select patients with painful bone metastases that progressed from prostate cancer. They might benefit from treatment with beta- or alpha-particle-emitting bone-seeking agents, the newest and most successful of which is 223Ra radium chloride. Somatostatin receptor targeting peptides for diagnosing and treating neuroendocrine tumors with agents such as 68Ga-DOTATATE and 177Lu-DOTATATE, respectively, are among the recently established theranostics.
Get Exclusive Sample PDF @: https://www.premiummarketinsights.com/sample/TIP00073774?utm_source=OpenPr&utm_medium=10640
The List of Companies -
1. Bayer AG
2. GE HealthCare Technologies Inc
3. Curium
4. Lantheus Medical Imaging, Inc.
5. Telix Pharmaceuticals Ltd.
6. Cardinal Health Inc
7. Advanced Accelerator Applications S.A.
8. Jubilant Radiopharma
9. Theragnostics
10. NuView Life Sciences
Cancer is one of the leading causes of death worldwide, responsible for almost 10 million deaths in 2020, or almost one in six. The most common types of cancer are breast, lung, colon, and prostate. According to National Cancer Registry Program Report 2020, in India, male cancer cases were estimated at 679,421 in 2020 and are expected to further increase to about 763,575 in 2025, while female cancer cases were estimated at 712,758 in 2020 and 806,218 in 2025. As people age, they become immunocompromised and often succumb to cancer risks. Poor lifestyles, longer working hours, increasingly stressful lives, smoking, alcohol consumption, contraceptive use, nulliparity, and reduced breastfeeding all contribute to breast cancer incidence.
According to the American Cancer Society's 2023 report, ~43,720 new cases of thyroid cancer (12,540 in men and 31,180 in women) are recorded in 2023. The report also revealed that 2,120 deaths occurred from thyroid cancer (970 in men and 1,150 in women) in the same year. Radiopharmaceutical theranostics have promising potential in cancer therapy. Theranostics is the combination of therapeutic and diagnostic techniques that utilize a suitable radiopharmaceutical agent. For example, radioiodine has a well-known theranostic application in diagnosing and treating differentiated thyroid cancer. Several radiopharmaceutical theranostic pairs are available for breast cancer applications. These pairs include 43/44Sc/47Sc, 64Cu/67Cu, 83Sr/89Sr, 86Y/90Y, 110In/111In, 124I/131I, 152Tb/161Tb, 152Tb/149Tb, 68Ga/177Lu, and 90Y/177Lu. 123I/131I is a well-known example of theranostic pair that is used in high-quality single-photon emission computerized tomography (SPECT)/CT for pre- and post-therapeutic assessment of thyroid cancer.
Get full Report Description, TOC, Table of Figure, Chart, etc. @: https://www.premiummarketinsights.com/reports-tip/radiopharmaceutical-theranostics-market
Malignant gliomas are deadly tumors with the availability of only a few therapeutic options. 89Zr- and 177Lu-labeled Lumi804-αCD11b is a promising theranostic technique intended for monitoring and reducing tumor-associated myeloid cells (TAMCs) in gliomas and improving immunotherapy outcomes. Further, theranostics are incorporated in radiometals for PET imaging and targeted radiopharmaceutical therapy (TRT). DOTA-octreotate (dotatate) radiolabeled with Lu-177 (177Lu-dotatate: Lutathera) or Ga-68 (68Ga-dotatate: NetSpot) are approved by the Food and Drug Administration (FDA) for targeted radiopharmaceutical therapy (TRT) and positron emission tomography (PET) imaging. Thus, a radiopharmaceutical theranostic approach has unprecedented value in diagnosing and treating different types of cancer, which fuels the overall radiopharmaceutical theranostics market growth.
Product Type Insights
Based on product type, the radiopharmaceutical theranostics market is segmented positron emission tomography (PET) tracers, beta emitters, and alpha emitters. In 2022, the positron emission tomography (PET) tracers segment held the largest market share in radiopharmaceutical theranostics market, and it is anticipated to register the highest CAGR during the forecast period (2022-2028). PET is an imaging technique that provides quantitative information on the distribution of PET radiopharmaceuticals in the body. PET imaging requires expensive equipment, which includes a cyclotron for radionuclide production, automated chemistry devices, purification instrumentation, and PET cameras.
PET imaging is used in areas such as cardiology, neurology, and cancer diagnosis. PET may detect the early onset of disease before it is evident on other imaging tests. Better resolution can be achieved via PET using positron emitters, such as gallium-68 and fluorine-18. PET tracers featuring radioactive copper have also been developed as a promising alternative for existing hypoxia imaging techniques due to their high membrane permeability and low redox potential. The success of Ga-PSMA-11 further inspired the development of PSMA-targeting PET tracers for imaging prostate cancer. Additionally, theranostics PET tracers are progressively used in radiopharmaceutical drug development and its application.
Theranostic PET tracers have the potential to serve as a noninvasive whole-body navigator, which helps select the most effective drug candidates, and determine optimal dosage and administration route. Thus, benefits such as higher resolution, and quantification of activity boost the radiopharmaceutical theranostics market for the PET tracers segment.
Radioisotope Insights
Based on radioisotope, the radiopharmaceutical theranostics market is segmented Lutetium (Lu) 177, Gallium-68, Iodine-131, Iodine-123, Technetium-99, Yttrium-90 (Y-90), Copper (Cu) 64, 18F, Copper (Cu) 67, and others. In 2022, the Lutetium (Lu) 177 segment held the largest market share in radiopharmaceutical theranostics market, and it is anticipated to register the highest CAGR of 12.3% during the forecast period (2022-2028). Lutetium-177 (177Lu) is the latest addition to the field of nuclear medicine. It has potential to become one of the most extensively used therapeutic radionuclides in the coming years. Lu-177 PSMA therapy for cancer theranostic is employed to treat advanced prostate cancer cases. Lu-177 octreotate therapy is used to treat neuroendocrine tumors (NETs), including head and neck cancers and gastrointestinal tumors. Lutetium therapy (lutetium-177-DOTA-oxodotreotide) has been identified as targeted radionuclide therapy or peptide receptor radionuclide therapy (PRRT). The US Food and Drug Administration (FDA) has approved 177Lu-labeled DOTA-TATE for peptide receptor radionuclide therapy (PRRT).
Buy this research report at @: https://www.premiummarketinsights.com/buy/TIP00073774?utm_source=OpenPr&utm_medium=10640
Source Insights
Based on source, the radiopharmaceutical theranostics market is divided into cyclotrons and nuclear reactors. In 2022, the cyclotrons segment held a larger market share in radiopharmaceutical theranostics market and is anticipated to register a higher CAGR during the forecast period (2022-2028). Cyclotrons are best suited for producing proton-rich radioisotopes such as Fluorine-18 (18F).
Commercially available cyclotron-produced medical radioisotope involves Carbon-11, Nitrogen-13, Oxygen-15, Fluorine-18 (18F), Copper-64, Gallium-67, Iodine-123, and Thallium-201. According to the International Atomic Energy Agency (IAEA) 2023 report, the most frequent radioisotope produced through cyclotrons are those with short half-lives, particularly fluorine-18, carbon-11, oxygen-15, and nitrogen-13, intended for imaging techniques such as positron emission tomography (PET). Cyclotrons account for almost 95% of the production of radiopharmaceuticals used in PET. Additionally, the demand for cyclotrons is increasing as radionuclides are majorly used in research, diagnosis, and treatment of a range of life-threatening diseases such as cancer, Parkinson's, Alzheimer's, and insomnia. Further, medical imaging techniques such as PET and SPECT depend on cyclotron-produced radioisotopes.
Application Insights
Based on application, the radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and companion diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in radiopharmaceutical theranostics market in 2022, and it is expected to register a higher CAGR during the forecast period. Targeted therapeutics have emerged as a promising strategy for treating harmful clinical conditions, such as cancer. For example, "radionuclide," a type of radiation therapy, uses a cell-targeting molecule such as a monoclonal antibody injected into the body. Further, the cell-targeting molecule binds to a specific target molecule on cancer cells, subsequently killing the targeted cancer cells; the mechanism ensures minimum harm to normal cells. Targeted therapeutics are used for treating prostate cancer and other types of cancers. This is well understood by the following case of targeting somatostatin receptors in neuroendocrine pancreatic tumors.
68Ga has been developed for somatostatin receptor imaging such as DOTATOC, DOTATATE, and DOTANOC. A somatostatin-receptor targeted therapy can be utilized for neoadjuvant therapy that renders inoperable pNET resectable by utilizing 177Lu-DOTATATE (27) and 90Y-DOTATATE (28). 90Y is a beta-emitting radionuclide best suited for bulky pancreatic tumors. Additionally, 177Lu-DOTATOC and 213Bi-DOTATOC have revealed relatively high biological effectiveness, and they are effectively responsible for decreasing the survival of pancreatic adenocarcinoma cells.
Indication Insights
Based on indication, the radiopharmaceutical theranostics market is segmented oncology, neurology, cardiology, and others. The oncology segment held the largest market share in radiopharmaceutical theranostics market in 2022, and it is anticipated to register the highest CAGR during the forecast period (2022-2028). Theranostics methods involve administering nanoparticles into the patient's body and using photodynamic therapy, which paves the way for personalized medicine. These methods can be applied in the treatment of esophageal cancer, prostate cancer, and breast cancer, in the treatment of actinic keratosis, actinic cheilitis, Bowen's disease, basal cell epithelioma, and macular degeneration.
Therapeutic radiopharmaceuticals for cancer treatment are predominantly labeled with beta-emitting radionuclides. The radionuclides I-131, Lu-177, and Yttrium-90 (Y-90) are frequently used for this purpose. Upon decay, the emitted beta-particles travel 1-12 mm through tissue while losing energy and causing cytotoxic damage to the cell to induce apoptosis. Alternatively, and more recently, alpha-emitting radionuclides, e.g., At-211 or Ac-225, have been explored for therapeutic applications. Theranostics has been successfully used by clinicians and patients in treating prostate cancer. Thus, the strong clinical need for these therapies and targeted treatments in oncology continue to fuel the market for the oncology segment during the forecast period.
End User Insights
Based on end user, the radiopharmaceutical theranostics market is segmented hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022 of global radiopharmaceutical theranostics market. However, academic and research institutes segment is anticipated to register the highest CAGR during the forecast period (2022-2028). Hospitals employ technologically advanced systems to treat cardiac aneurysms, neurology aneurysms, oncology tumors, and other similar conditions. The rising prevalence of various diseases and an increasing number of hospitals contribute to the growth of the radiopharmaceutical theragnostic market for hospitals segment.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 by Product Type
1.3.2 by Radioisotope
1.3.3 by Source
1.3.4 by Application
1.3.5 by Indication
1.3.6 by End User
1.3.7 by Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 South & Central America PEST Analysis
4.2.5 Middle East & Africa PEST Analysis
4.3 Expert's Opinion
5. Key Market Dynamics
Continued…
Other Reports:
Smart Pest Monitoring Management System Market Growth, Future Prospects And Competitive Analysis (2022-2028 https://www.marketwatch.com/press-release/smart-pest-monitoring-management-system-market-growth-future-prospects-and-competitive-analysis-20222028-2023-05-12?mod=search_headline
Traffic Management Market Size, Share, Global Trends, Major Key Players and Geographical Forecast Till 2028 https://www.marketwatch.com/press-release/traffic-management-market-size-share-global-trends-major-key-players-and-geographical-forecast-till-2028-2023-05-12?mod=search_headline
Wire And Cable Market by Historical Data, Segmentation, Growth Opportunities Forecast till 2028 https://www.marketwatch.com/press-release/wire-and-cable-market-by-historical-data-segmentation-growth-opportunities-forecast-till-2028-2023-05-12?mod=search_headline
Aircraft Isothermal Forging Market Size, Share & Global Insights 2022-2028 https://www.marketwatch.com/press-release/aircraft-isothermal-forging-market-size-share-global-insights-2022-2028-2023-05-12?mod=search_headline
Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email: sales@premiummarketinsights.com
About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
